15.71
Bausch Lomb Corp stock is traded at $15.71, with a volume of 306.08K.
It is up +0.51% in the last 24 hours and up +3.02% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$15.63
Open:
$15.55
24h Volume:
306.08K
Relative Volume:
0.47
Market Cap:
$5.56B
Revenue:
$4.89B
Net Income/Loss:
$-263.00M
P/E Ratio:
-20.31
EPS:
-0.7734
Net Cash Flow:
$-167.84M
1W Performance:
+4.94%
1M Performance:
+3.02%
6M Performance:
+25.78%
1Y Performance:
-22.80%
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BLCO
Bausch Lomb Corp
|
15.71 | 5.53B | 4.89B | -263.00M | -167.84M | -0.7734 |
![]()
ISRG
Intuitive Surgical Inc
|
527.03 | 165.88B | 9.15B | 2.63B | 1.99B | 7.1661 |
![]()
BDX
Becton Dickinson Co
|
188.11 | 54.18B | 21.39B | 1.61B | 2.55B | 5.5609 |
![]()
RMD
Resmed Inc
|
266.48 | 39.14B | 5.15B | 1.40B | 1.65B | 9.5082 |
![]()
ALC
Alcon Inc
|
76.40 | 37.46B | 10.03B | 1.07B | 1.39B | 2.1549 |
![]()
WST
West Pharmaceutical Services Inc
|
277.00 | 20.09B | 2.96B | 487.70M | 344.00M | 6.6758 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-01-25 | Initiated | Goldman | Neutral |
May-02-25 | Reiterated | H.C. Wainwright | Buy |
Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
Jul-10-24 | Initiated | Raymond James | Outperform |
May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-12-23 | Initiated | Stifel | Hold |
Oct-03-23 | Resumed | Evercore ISI | Outperform |
May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
Mar-09-23 | Initiated | Needham | Hold |
Dec-21-22 | Initiated | Barclays | Equal Weight |
Sep-12-22 | Initiated | H.C. Wainwright | Buy |
Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
Jun-24-22 | Initiated | Evercore ISI | Outperform |
Jun-06-22 | Initiated | Citigroup | Buy |
May-31-22 | Initiated | Deutsche Bank | Hold |
May-31-22 | Initiated | Goldman | Neutral |
May-31-22 | Initiated | Guggenheim | Buy |
May-31-22 | Initiated | JP Morgan | Neutral |
May-31-22 | Initiated | Jefferies | Buy |
May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
May-31-22 | Initiated | Wells Fargo | Overweight |
May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
Published on: 2025-10-21 20:10:31 - newser.com
Is Bausch + Lomb Corporation (S2L) stock a momentum leaderOptions Play & Risk Controlled Stock Pick Alerts - newser.com
BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛
Is Bausch + Lomb Corporation (S2L) stock worth buying before Fed actionWeekly Trading Summary & Fast Entry Momentum Trade Alerts - newser.com
Will Bausch + Lomb Corporation stock announce special dividendGap Down & Weekly Return Optimization Plans - newser.com
Applying big data sentiment scoring on Bausch + Lomb CorporationJuly 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Potential CooperVision–Bausch + Lomb merger floated by investor - Rochester Business Journal
Why global investors buy Bausch + Lomb Corporation stockWeekly Market Summary & Fast Momentum Stock Entry Tips - newser.com
Will Bausch + Lomb Corporation stock benefit from commodity supercycleQuarterly Trade Report & Weekly Setup with High ROI Potential - newser.com
Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know - Yahoo Finance
Activist investor Jana Partners takes stake in Cooper Companies, sources say - Reuters
Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb - Benzinga
Is Bausch + Lomb Corporation stock safe for conservative investorsJuly 2025 Volume & Free Community Consensus Stock Picks - newser.com
3 Stocks Under $50 We Steer Clear Of - The Globe and Mail
Bausch + Lomb Corporation (BLCO) Receives a Hold from Stifel Nicolaus - The Globe and Mail
What does recent volatility data suggest for Bausch + Lomb Corporation2025 Short Interest & Long-Term Growth Portfolio Plans - newser.com
Contact Lenses Market Trends, Shares, Strategies and Growth Analysis Report (2025-2034) Featuring Alcon Vision, Bausch & Lomb, J&J Vision Care, CooperVision, Essilor International and More - GlobeNewswire Inc.
Earnings call transcript: Bausch + Lomb sees revenue growth in Q2 2025 - Investing.com India
Bausch + Lomb Q2 2025 slides: Revenue grows 3% as company raises full-year guidance - Investing.com Australia
Earnings call transcript: Bausch + Lomb sees revenue growth in Q2 2025 By Investing.com - Investing.com South Africa
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Stifel reiterates Buy rating on Bausch & Lomb stock, maintains $12 price target - Investing.com UK
Bausch + Lomb (NYSE:BLCO): Evaluating Valuation After Recent Earnings and Share Price Moves - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Forecasts - Yahoo Finance
Analyzing drawdowns of Bausch + Lomb Corporation with statistical toolsMarket Movement Recap & Community Driven Trade Alerts - newser.com
Bausch + Lomb's (BLCO) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Bausch + Lomb (NYSE:BLCO) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
What drives Bausch Lomb Corporation stock priceVolume Spike Alerts & Fast Growing Capital Growth - earlytimes.in
Bausch + Lomb Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
Can Bausch + Lomb Corporation (S2L) stock deliver strong annual returnsShare Buyback & Step-by-Step Trade Execution Guides - newser.com
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $16 - 富途牛牛
Assessing Bausch + Lomb (NYSE:BLCO) Valuation as Goldman Sachs Brings New Spotlight to Ophthalmology Growth Prospects - simplywall.st
Bausch + Lomb (NYSE:BLCO) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Applying Elliott Wave Theory to Bausch + Lomb CorporationQuarterly Market Review & Comprehensive Market Scan Reports - newser.com
Why Bausch + Lomb Corporation stock is upgraded to buy2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - newser.com
Goldman Sachs Initiates Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Announces Target Price $16 - 富途牛牛
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating - Investing.com
Is Zeal Aqua Limited a Smart Pick for Retirement PortfoliosEx-Dividend Date Alerts & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13 - BioSpace
Is Bausch + Lomb Corporation stock positioned for digital transformationMarket Growth Review & AI Driven Stock Reports - newser.com
Global Eye Health Leader Bausch + Lomb Announces Q3 Earnings Date and Strategic Investor Day Pipeline Review - Stock Titan
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):